Results 201 to 210 of about 82,077 (257)
Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines
Vox Sanguinis, EarlyView.
Pierre Tiberghien +4 more
wiley +1 more source
Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein
Chemistry–Methods, Volume 6, Issue 5, May 2026.The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley +4 more
wiley +1 more source
Computational Design of an mRNA Vaccine Targeting LRP6 for Triple‐Negative Breast Cancer Therapy
Cancer Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background Triple‐negative breast cancer (TNBC) presents a poorer prognosis than other breast cancer subtypes, attributed to its aggressive nature and the lack of specific therapeutic interventions. TNBC has high recurrence rates and limited survival despite current therapies, emphasizing the critical need for improved treatment options.
Pooriya Teimoori, Mohammadreza Heidari
wiley +1 more source
Food Science &Nutrition, Volume 14, Issue 5, May 2026.Lactiplantibacillus plantarum CQPC03 could reduce carrageenan‐induced thrombosis in mice. ABSTRACT This investigation reports the effects of Lactiplantibacillus plantarum CQPC03 (LP‐CQPC03) on preventing thrombus formation and reducing intestinal oxidative stress and inflammation in a carrageenan‐induced mouse thrombosis model. High‐throughput 16S rRNA
Xin Zhao +6 more
wiley +1 more source
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background and Aims Acute respiratory tract infections (ARTIs) are a primary cause of mortality in Bangladesh, yet the Human Metapneumovirus (hMPV) remains critically underdiagnosed. This perspective aims to evaluate the current diagnostic landscape, identify specific surveillance gaps, and propose a prioritized strategic framework for ...
Abdullaha Al Mamun +1 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Recombinant bacterial vaccines
Current Opinion in Immunology, 2012Vaccines are currently available for many infectious diseases caused by several microbes and the prevention of disease and death by vaccination has profoundly improved public health globally. However, vaccines are not yet licensed for use against many other infectious diseases and new or improved vaccines are needed to replace suboptimal vaccines, and ...
Meera, Unnikrishnan +2 more
openaire +2 more sources
Recombinant vaccines against Leptospirosis
Human Vaccines, 2011Leptospirosis is an important neglected infectious disease that occurs in urban environments, as well as in rural regions worldwide. Rodents, the principal reservoir hosts of pathogenic Leptospira spp., and other infected animals shed the bacteria in their urine.
Odir A, Dellagostin +5 more
openaire +2 more sources
Recombinant Therapeutic Protein Vaccines
Protein & Peptide Letters, 2013Recombinant technology has ushered in a new era for the pharmaceutical industry. Protein therapeutics, including plasma-derived products and antibodies obtained from the serum of infected patients, have been successfully adopted and utilized to treat various indications.
Satoshi, Ohtake, Tsutomu, Arakawa
openaire +2 more sources
Recombinant Vaccines: The Revolution Ahead
2022The post-vaccination era has boosted constant innovations in the field of medicine and public health and has been instrumental in greatly augmenting the quality of life of human civilization. Ground-breaking scientific innovations in the twentieth and twenty-first centuries have enabled coherent vaccine design and the creation of novel vaccines for a ...
openaire +2 more sources